Oral pill Orforglipron delivers stellar results in Phase 3 Trial
Eli Lilly's new drug oral GLP1 Orforglipron delivers fantastic results in phase 3 trial -- 7.6% weight loss for just a pill!
Most GLP1 Receptor Agonists are injected, but there are a few products developed by Novo Nordisk and Eli Lilly (the largest GLP1-focused pharmaceutical companies) that can be taken orally.
🍃
Don't know what a GLP1 Receptor Agonist is, or how drugs like Ozempic, Mounjaro, Wegovy, or Zepbound work?
Check out our quick explainer
Check out our quick explainer
Novo Nordisk created Rybelsus, which has been up until now the only FDA approved oral GLP1, but Eli Lilly has been hard at work on it's own oral GLP1 – Orforglipron:
Eli Lilly’s other new GLP1 - Orforglipron
Eli Lilly is developing new GLP1 drugs, and Orforglipron is one of them. It’s not easy to pronounce, but it is easy to take, and easy to produce.
GLP1.Guide Staff
Want to read the rest of our analysis on Orforglipron and the papers and trials we found? Read the rest of our analysis, check us out on Substack:
